Next Article in Journal
Therapeutic Strategies for Chromium-Induced Neurotoxicity: Exploiting NPTX2 and Autophagy Pathways in CNS Cells
Previous Article in Journal
Cathepsin B-Induced Degradation of Lysozyme Amyloid Fibrils
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

In Silico Prediction of Drug-Likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids †

by
Obinna Kenneth Didigwu
1,*,
Emmanuel Amuchechukwu Kevin
2,
Michael Osita Edeh
2 and
Sunday N. Okafor
1
1
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu 410001, Nigeria
2
Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu 410001, Nigeria
*
Author to whom correspondence should be addressed.
Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: https://sciforum.net/event/IECBM2024.
Proceedings 2024, 103(1), 20; https://doi.org/10.3390/proceedings2024103020
Published: 12 April 2024
(This article belongs to the Proceedings of The 3rd International Electronic Conference on Biomolecules)
Pyrrolizidine alkaloids (PAs) are heterocyclic organic compounds of natural origin synthesized by either plants or microorganisms. They are found in species applied in the pharmaceutical industry for their beneficial biological activities to cure disease; thus, a thorough knowledge of their pharmacokinetics and toxicity is of great importance as they are notorious for their acute hepatotoxicity and carcinogenicity in humans and animals. Therefore, this study evaluated the drug-likeness of 15 phytotoxic pyrrolizidine alkaloids that were reportedly isolated from 11 plant species via in silico prediction of their pharmacokinetic and toxicity profiles. Using Swiss ADME, pkCSM, and PreADMET webserver tools, Lipinski’s properties and topological polar surface area (TPSA) were predicted for drug-likeness, alongside their pharmacokinetic profiles and toxicity on various organ endpoints. The drug-likeness prediction showed that all the compounds obeyed Lipinski’s rule of five (LRo5). None of the compounds inhibited hERG I and hERG II, indicating their non-cardiotoxic nature. In addition, 20% of the compounds elicited AMES toxicity; 53.33% caused liver injury; and none was sensitive to the skin. Furthermore, 13.33% showed high Caco-2 permeability and all displayed good skin permeability, implying their suitability for transdermal drug delivery. Moreover, P-glycoprotein was effluxed by 80% of the compounds and none exhibited inhibition; 86.66% of the compounds readily crossed the blood–brain barrier, 6.66% penetrated the central nervous system, none was a substrate to cytochrome p450 isoenzymes, 6.66% inhibited cytochrome p450 isoenzymes, 53.33% and 26.66% would cause cancer in mice and rats, respectively, and 20% showed high tolerated doses in humans. All demonstrated high intestinal absorption and 46.66% demonstrated good water solubility while a significant number showed a moderate volume of distribution, were free-flowing in plasma, and demonstrated moderate bioavailability. This study identified Jacoline and monocrotaline as drug-like, non-toxic, and highly bioavailable pyrrolizidine alkaloids with strong potential for further assessment, optimization, and development.

Author Contributions

Conceptualization, O.K.D. and E.A.K.; methodology, S.N.O.; software, E.A.K. and M.O.E.; validation, O.K.D., E.A.K. and M.O.E.; formal analysis, O.K.D.; writing—original draft preparation, E.A.K.; writing—review and editing, S.N.O.; visualization, O.K.D.; supervision, S.N.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data supporting the result of the study are yet to be uploaded.

Conflicts of Interest

The authors declare no conflicts of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Didigwu, O.K.; Kevin, E.A.; Edeh, M.O.; Okafor, S.N. In Silico Prediction of Drug-Likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids. Proceedings 2024, 103, 20. https://doi.org/10.3390/proceedings2024103020

AMA Style

Didigwu OK, Kevin EA, Edeh MO, Okafor SN. In Silico Prediction of Drug-Likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids. Proceedings. 2024; 103(1):20. https://doi.org/10.3390/proceedings2024103020

Chicago/Turabian Style

Didigwu, Obinna Kenneth, Emmanuel Amuchechukwu Kevin, Michael Osita Edeh, and Sunday N. Okafor. 2024. "In Silico Prediction of Drug-Likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids" Proceedings 103, no. 1: 20. https://doi.org/10.3390/proceedings2024103020

APA Style

Didigwu, O. K., Kevin, E. A., Edeh, M. O., & Okafor, S. N. (2024). In Silico Prediction of Drug-Likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids. Proceedings, 103(1), 20. https://doi.org/10.3390/proceedings2024103020

Article Metrics

Back to TopTop